Evidence map›Paper›PMID 35911415›Full record

ArticleFrontiers in medicine2022

Development and Validation of a Non-invasive Model to Predict Liver Histological Lesions in Chronic Hepatitis B Patients With Persistently Normal Alanine Aminotransferase and Detectable Viremia.

Qiankun Hu, Qianqian Wang, Wei Xu, Chenlu Huang, Shuai Tao, Xun Qi, Yi Zhang, Xinyan Li, Xuhua Jiang, Jie Song and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Qiankun HuDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qianqian WangDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Wei XuDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Chenlu HuangDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shuai TaoDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xun QiDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yi ZhangDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xinyan LiDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xuhua JiangDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jie SongDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qiang LiDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Liang ChenDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yuxian HuangDepartment of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A critical and controversial issue is whether antiviral therapy should be recommended in chronic hepatitis B virus (HBV) infection patients with persistently normal alanine aminotransferase (PNALT) and detectable HBV DNA. The study aimed to develop a non-invasive model for predicting significant liver histological changes (SLHC), which is the histological indication for antiviral therapy in chronic hepatitis B (CHB) patients with PNALT and detectable HBV DNA. Methods: 398 chronic HBV infection patients with PNALT and detectable HBV DNA who underwent liver biopsy were divided into the estimation set ( Results: 132 patients (33.2%) with PNALT and detectable HBV DNA had SLHC. Aspartate aminotransferase (AST), cholinesterase (ChE), and liver stiffness measurement (LSM) were identified as the independent predictors of SLHC. The AUROC of the SLHC index, which combined AST, ChE, and LSM, was 0.824 and 0.816 in the estimation and validation set, respectively, for the prediction of SLHC. Applying the SLHC index ≤ 0.15, the presence of SLHC could be excluded with high negative predictive value in the estimation set (93.2%) and in the validation set (90.2%). Applying the SLHC index ≥ 0.55, the presence of SLHC could be considered with high positive predictive value in the estimation set (79.2%) and in the validation set (76.5%). Conclusion: The SLHC index provides a high accuracy in predicting liver histological indication for antiviral therapy in CHB patients with PNALT and detectable HBV DNA.

Indexed as

antiviral therapychronic hepatitis Bnon-invasive modelpersistently normal alanine aminotransferasesignificant liver histological changes

Identifiers

PMID35911415
PMCPMC9326251
OpenAlexW4285083570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.